The global industry was valued at US$ 652.2 Mn in 2022 and is estimated to grow at a CAGR of 6.1% from 2023 to 2031, reaching US$ 1.1 Bn by the end of 2031. The thrombin market is experiencing significant growth due to the increasing prevalence of surgical procedures, rising incidence of chronic diseases, and growing demand for advanced hemostatic solutions in healthcare settings. Thrombin, a critical enzyme involved in blood coagulation, is widely used in surgical applications to control bleeding and support wound healing. As healthcare systems worldwide continue to focus on improving patient outcomes and minimizing surgical complications, the demand for thrombin-based products is expected to rise steadily over the forecast period.

Access our report for a comprehensive look at key insights - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=19580

Market Overview

The thrombin market has evolved considerably with advancements in biotechnology and surgical care. Thrombin products are extensively utilized in hospitals, trauma centers, and ambulatory surgical facilities due to their effectiveness in achieving rapid hemostasis during complex medical procedures. Increasing numbers of orthopedic, cardiovascular, and neurological surgeries are driving market demand, particularly as aging populations and chronic health conditions continue to rise globally. Additionally, ongoing innovation in recombinant and bovine thrombin products is improving safety profiles and expanding application areas. The healthcare industry’s growing emphasis on minimally invasive procedures and faster recovery times is further accelerating adoption of thrombin-based hemostatic agents.

Market Size and Growth

Valued at US$ 652.2 Mn in 2022, the thrombin market is projected to reach US$ 1.1 Bn by 2031, growing at a CAGR of 6.1%. This growth is supported by increasing healthcare expenditures, expanding access to surgical care, and rising awareness regarding effective blood management techniques. The growing incidence of trauma injuries and emergency surgeries is also contributing to market expansion. Furthermore, technological advancements in biologics manufacturing and the development of highly purified thrombin formulations are creating new opportunities for industry participants. The steady growth trajectory highlights the essential role thrombin plays in modern surgical and wound care practices.

Market Segmentation

The thrombin market can be segmented based on product type, application, and end-user. By product type, the market includes bovine thrombin, human thrombin, and recombinant thrombin, with recombinant thrombin gaining traction due to reduced risk of immunogenic reactions and enhanced safety. In terms of application, thrombin is widely used in surgery, wound management, and tissue sealing, with surgical applications accounting for a major share of the market. End-users include hospitals, ambulatory surgical centers, and specialty clinics, where the increasing number of complex surgical interventions continues to fuel demand. The growing preference for advanced hemostatic products is also influencing product development and market trends.

Regional Analysis

Regionally, North America dominates the thrombin market due to its advanced healthcare infrastructure, high surgical procedure volumes, and strong presence of leading pharmaceutical and biotechnology companies. Europe follows closely, supported by rising healthcare investments and increasing adoption of advanced surgical technologies. Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by expanding healthcare infrastructure, growing medical tourism, and increasing awareness regarding modern hemostatic solutions in countries such as China and India. Meanwhile, Latin America and the Middle East & Africa are emerging markets, offering growth opportunities as healthcare access and surgical capabilities continue to improve.

Competitive Landscape

The thrombin market is characterized by the presence of several established pharmaceutical and biotechnology companies competing through product innovation, strategic collaborations, and geographic expansion. Some of the leading companies operating in the industry include Johnson & Johnson, Pfizer, Inc., Mallinckrodt Pharmaceuticals, Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd., BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc. These companies are actively investing in research and development to enhance product safety, efficacy, and application versatility. Strategic partnerships and regulatory approvals remain key focus areas for market participants seeking to strengthen their competitive positions.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453